Effects of microRNA-378 on epithelial-mesenchymal transition, migration, invasion and prognosis in gastric carcinoma by targeting BMP2
Y.-J. Yang, S. Luo, L.-S. Wang Department of Gastroenterology, Shenzhen People’s Hospital, Shenzhen, China. wangls168@163.com
OBJECTIVE: Gastric cancer (GC) is a common malignancy. Recent studies have suggested that microRNAs are crucial factors in tumorigenesis. Thus, we investigated the effect of miR-378 on GC metastasis and further explored the underlying mechanism.
PATIENTS AND METHODS: Quantitative Real-time polymerase chain reaction (qRT-PCR) was carried out to measure the miR-378 expressions in GC and adjacent normal tissue samples. MiR-378 expressions in human GC cells were determined using qRT-PCR and Western blots. Moreover, transwell assays were conducted to measure the invasion and migration capacities of GC cells. Additionally, the regulating effects on BMP2 by miR-378 were assessed by luciferase reporter assays and western blots. Western blot was also carried out to observe the protein expressions of epithelial-mesenchymal transition (EMT) related genes.
RESULTS: MiR-378 expressions in GC tissues were downregulated. In the meantime, reduced miR-378 expression was associated with poor prognosis and malignant clinicopathologic features of GC patients. MiR-378 overexpression repressed GC cell invasion, migration and EMT. Furthermore, BMP2 was a direct target of miR-378 and implicated in miR-378-mediated suppressive functions in GC invasion, migration and EMT.
CONCLUSIONS: We showed that miR-378 served as a tumor suppressor in GC via modulating BMP2, suggesting that miR-378/BMP2 axis might be therapeutic targets and promising biomarkers for GC treatment.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
Y.-J. Yang, S. Luo, L.-S. Wang
Effects of microRNA-378 on epithelial-mesenchymal transition, migration, invasion and prognosis in gastric carcinoma by targeting BMP2
Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 12
Pages: 5176-5186
DOI: 10.26355/eurrev_201906_18182